Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

iShares Russell 2000 BuyWrite ETF (NY:IWMW)

39.54 -0.04 (-0.10%)
Streaming Delayed Price Updated: 1:55 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iShares Russell 2000 BuyWrite ETF

< Previous 1 2 3 4 Next >
Novavax COVID-19 Vaccine Approved In Japan, Triggers Milestone Payment From Partner Takeda ↗
Via Stocktwits
FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film ↗
Via Stocktwits
Wave Life Sciences Tumbled 19% Today, But Not Everyone’s Disappointed – Find Out Why ↗
Via Stocktwits
Tectonic Stock Soars Pre-market After Tuesday’s Sell-Off: Oppenheimer Is Hopeful About Company’s Lead Candidate ↗
Via Stocktwits
News headline image
Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update ↗
The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer. 
Via Stocktwits
News headline image
US FDA Withdraws Approval For Amylyx’s Neurodegenerative Disorder Drug, But BofA Hikes Price Target ↗
Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company reiterated earlier this week that it has a... 
Via Stocktwits
Dynavax’s Experimental Shingles Vaccine Shows Positive Results In Study: Retail Expects Stock Rally To Continue Into Friday ↗
Via Stocktwits
Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’ ↗
Via Stocktwits
Vanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-Mark ↗
Via Stocktwits
PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided ↗
Via Stocktwits
This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’ ↗
Via Stocktwits
Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet ↗
Via Stocktwits
This Aviation Stock Has Doubled In 2025, Surged Over 200% In 12 Months, And Is Trending On Friday – Do You Own It? ↗
Via Stocktwits
News headline image
Precigen Stock Shot Through The Roof On Friday Morning – Here’s Why ↗
The company stated that Papzimeos is now the first and only FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis. 
Via Stocktwits
News headline image
Hertz Expands Program Allowing Prolonged 3-Day Test Drives Before Vehicle Purchase To Over 100 Cities ↗
Consumers can test the vehicles for up to three days before purchasing at a low daily rate. 
Via Stocktwits
Aquestive Therapeutics Stock Is Rising Pre-Market – Its $75M Funding Agreement Draws Divided Opinions From Retail ↗
Via Stocktwits
Schrödinger Discontinues Clinical Program After Two Patient Deaths ↗
Via Stocktwits
Novavax CFO Says Sanofi To Cover Majority Of Future Nuvaxovid Study Costs, Retail Urges Partnership Diversification ↗
Via Stocktwits
Ardelyx Stock Soars On Price Target Hikes After Upbeat Q2 Report: Retail Sees More Revisions Coming ↗
Via Stocktwits
News headline image
TG Therapeutics Stock Tumbles 15% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug ↗
The company raised its Briumvi U.S. net product revenue target to $570 million to $575 million for the full year 2025, up from its previous guidance of $560 million. 
Via Stocktwits
Topics Earnings
News headline image
BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level ↗
CEO Jon Stonehouse stated during the company’s earnings call on Monday that the firm’s Netherton Syndrome and DME pipeline programs remain on track to have some data by the end of the year. 
Via Stocktwits
Topics Artificial Intelligence Earnings
News headline image
CervoMed Dementia Drug Slows Disease Progression In Study: Retail Loads Up On The Stock ↗
The company is now poised to initiate late-stage trials for Neflamapimod. 
Via Stocktwits
News headline image
This Pharma Stock Rose 200% On Monday Morning And Retail Says Valuation Could Rise To $5B: Here’s Why ↗
Sara Hurvitz, co-principal investigator for the trial, said that the data for both combination treatments in the trials are “potentially practice-changing.” 
Via Stocktwits
Topics Death
Novavax Announces Positive Preclinical Data From Bird Flu Vaccine: Retail Wonders When Will The Stock Be Fairly Valued ↗
Via Stocktwits
Oscar Health Now Expects Loss From Operations Of $200M To $300M In 2025: Here’s What Retail Thinks About The Stock Price ↗
Via Stocktwits
News headline image
Joby Aviation Stock Flies High On Expansion Of Marina Site, Retail Boards The Flight ↗
Once fully operational, the expanded Marina site is expected to be capable of producing up to 24 aircraft per year, or nearly one every other week. 
Via Stocktwits
News headline image
Capricor Stock Plunges Pre-Market After US FDA Declines Approval For Muscular Disorder Therapy ↗
The FDA told Capricor in a letter that it is unable to approve its application for Deramiocel in its current form as it does not meet the requirement for substantial evidence of effectiveness and... 
Via Stocktwits
News headline image
Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity ↗
Rhythm now plans to seek input from U.S. and EU regulatory authorities on a late-stage trial design to advance Bivamelagon in acquired hypothalamic obesity. 
Via Stocktwits
Topics Government
News headline image
KalVista Stock Soars Pre-Market On FDA Approval For Drug In Treating Swelling Disorder: Retail’s Elated ↗
Ekterly is the first and only oral on-demand treatment for hereditary angioedema, KalVista said, setting it apart from other on-demand treatment options approved in the U.S., which require intravenous... 
Via Stocktwits
News headline image
BioCryst To Sell European Business Of Its Hereditary Angioedema Drug To Pay Off Debt: Stock Rises While Retail Stays Bearish ↗
As per the terms of the agreement, Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to Orladeyo and the company will also be eligible to receive up... 
Via Stocktwits
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.